2011 GRC & GRS on Cell Biology of Megakaryocytes and Platelets

描述(由申请者提供)：戈登研究会议(GRC)关于巨核细胞和血小板的细胞生物学，是主要的科学会议，重点是巨核细胞和由此产生的血小板的生物学。这将是史蒂夫·沃森和乔恩·弗兰普顿于2005年首次组织的第四次两年一度的会议，目的是让两组目标和兴趣相投的科学家聚集在一起。我们的会议将从造血/巨核细胞生物学开始，扩展到血小板生物发生和血小板(病理)生物学。演讲将集中于在发育的不同阶段形成巨核细胞的最新进展，并涵盖对转录、miRNA和表观遗传调控途径的新见解。接下来将报道围绕血小板生成的生物学事件，然后是影响巨核细胞生成和血小板生成的疾病，重点是骨髓增生性疾病。将介绍血小板中新的受体系统和细胞内途径，以及它们对血栓形成、繁殖、稳定性和溶解的贡献机制，还将介绍一场关于血小板中已建立的途径的会议，以及对这些过程的新见解如何有助于我们对止血和血栓形成的理解。通过致力于研究巨核细胞和血小板生物学中最先进的基因组和生物信息学的会议，将获得新的观点。最后一次会议将致力于调节血小板病理的途径和细胞机制。GRC与为期两天的戈登研究研讨会(GRS)相结合，为对这一领域感兴趣的学员提供机会，展示他们的研究成果，并从该领域的高级学术和行业调查人员那里获得见解。最佳实习生报告也将作为主要会议上3-4个青年调查员讲座的一部分介绍。将安排一次GRS和四次GRC海报会议，为初级和高级调查人员提供一个额外的论坛，以建立网络和交流想法。GRS和GRC会议分别于2011年3月19日至20日和20日至25日在位于墨西哥湾的德克萨斯州加尔维斯顿岛美丽的历史悠久的加尔韦斯酒店举行。这里拥有宽阔的海滩和岛上及附近众多景点的独特环境，对于所有与会者来说，这将是一个令人兴奋和难忘的场所。 与公共健康相关：血小板对正常的凝血至关重要，是病理性血栓的主要贡献者，如导致主要心血管疾病、心脏病发作和中风的血栓。本申请申请部分资助第四届戈登研究会议(GRC)关于巨核细胞和血小板的细胞生物学以及第一届卫星戈登-凯南受训人员研究研讨会的组织和运行费用。对血小板和产生血小板的巨核细胞的潜在生物学的最新介绍和讨论将与年轻研究人员的指导经验相结合，总体目标是提出新的见解，以改善心血管疾病的预防和护理。

DESCRIPTION (provided by applicant): The Gordon Research Conference (GRC) on the Cell Biology of Megakaryocytes and Platelets is the premier scientific meeting focused on the biology of megakaryocytes and the platelets that arise from them. This will be the 4th biennial meeting that was first organized by Steve Watson and Jon Frampton in 2005 to bring together two groups of scientists with complimentary goals and interests. Our meeting will begin with the biology of hematopoiesis/megakaryopoiesis and extend to platelet biogenesis and platelet (patho)biology. Presentations will focus on state-of-the-art advances in the formation of megakaryocytes at various stages of development and covering new insights into transcriptional, miRNA and epigenetic regulatory pathways. This will be followed by coverage of the biological events surrounding thrombopoiesis and then disorders that affect megakaryopoiesis and thrombopoiesis, focusing on the myeloproliferative diseases. New receptor systems and intracellular pathways in platelets and mechanisms of their contribution to clot formation, propagation, stability and resolution will be presented, as will a session on established pathways in platelets and how new insights into these processes have also contributed to our understanding of hemostasis and thrombosis. New perspectives will be gained via a session devoted to state- of-the-art genomic and bioinformatics in the study of megakaryopoiesis and platelet biology. The final session will be devoted to pathways and cellular mechanisms that regulate platelet pathologies. This GRC is tied in with a two-day Gordon Research Seminar (GRS) for trainees interested in this field and will give trainees the opportunity to present their research as well as gain insights from senior academic and industry investigators in this area. The best trainee presentations will also be presented as part of a series of 3-4 Young Investigator talks at the main conference. One GRS and four GRC poster sessions will be scheduled, giving junior and senior investigators an additional forum to network and exchange ideas. The GRS and GRC meetings take place from March 19-20th and 20-25th, 2011, respectively, at the beautiful, historic Hotel Galvez, Galveston Island, Texas, located on the Gulf of Mexico. With the unique surroundings of wide beaches and numerous attractions on and near the island, this will be an exciting and memorable venue for all attendees. PUBLIC HEALTH RELEVANCE: Platelets are critical for normal clotting and are a major contributor to pathologic thrombi such as those that underlie the major cardiovascular diseases, heart attacks and strokes. This application request partial support for the costs of organizing and running the 4th Gordon Research Conference (GRC) on the Cell Biology of Megakaryocytes and Platelets and the 1st satellite Gordon-Kenan Research Seminar for trainees. State-of-the- art presentations and discussions of the underlying biology of platelets and the megakaryocytes that give rise to platelets will be coupled to mentoring experiences for young investigators with the overall goal of advancing new insights to improve prevention and care of cardiovascular diseases.